Fig. 1

Number of first-time episodes of nonarteritic anterior ischemic optic neuropathy (NAION) and persons with type 2 diabetes (T2D) redeeming at least one prescription of once-weekly semaglutide (Ozempic^®) between January 1, 2010, and June 30, 2024